NCT06776198View on ClinicalTrials.gov

Precision Therapy Based on Immune Microenvironment by Transcriptome Sequencing of Osteosarcoma, a Prospective, Multi-cohort Exploratory Clinical Study

Not yet recruitingOBSERVATIONAL

Enrollment

100

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

March 1, 2026

Study Completion Date

June 1, 2027

Conditions

OsteosarcomaTranscriptomeTumor MicroenvironmentPrecision Medicine

Interventions

DRUG

Chemotherapy

Group IE/F: After progression, try LRRC15 ADC + PD-1 inhibitors; Group IE: After progression, try simple anti-PD-1 inhibitors; Group F: After progression, try LRRC15 ADC; Group D: After progression, try B7-H3 ADC or other irrinotecan analogue

All Listed Sponsors

lead

Peking University People's Hospital

OTHER

NCT06776198 - Precision Therapy Based on Immune Microenvironment by Transcriptome Sequencing of Osteosarcoma, a Prospective, Multi-cohort Exploratory Clinical Study | Biotech Hunter | Biotech Hunter